Dashboard
Manage Tickers

ABBV


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

peering-into-abbvies-recent-short-interest
Peering Into AbbVie's Recent Short Interest
09/06/2024 19:30:22

psychedelic-drugs-market-set-to-grow-by-137b-by-2028-driven-by-mental-health-disorders-and-ai-integration
Psychedelic Drugs Market Set To Grow By $1...
09/05/2024 16:53:46

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...

heres-how-much-100-invested-in-abbvie-10-years-ago-would-be-worth-today
Here's How Much $100 Invested In AbbVie 10...
09/05/2024 15:00:22

abbvie-announces-vraylar-receives-reimbursement-recommendation-from-canadas-drug-agency-for-treatment-of-schizophrenia-in-adults-following-successful-negotiations-and-loi
AbbVie Announces VRAYLAR Receives Reimburs...
09/04/2024 12:02:08

VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada on April 22, 2022.Following...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
09/03/2024 17:35:17

abbvie-options-trading-a-deep-dive-into-market-sentiment
AbbVie Options Trading: A Deep Dive into M...
08/29/2024 19:31:56

as-regulators-gear-up-to-decide-on-bristol-myers-schizophrenia-treatment-neurocrine-biosciences-data-disappoints-investors
As Regulators Gear Up To Decide On Bristol...
08/28/2024 15:16:26

Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms,...

regulators-expected-to-approve-innovative-schizophrenia-treatment-from-bristol-myers-karuna
Regulators Expected To Approve Innovative ...
08/27/2024 19:22:11

Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomb...

abbvie-unusual-options-activity-for-august-26
AbbVie Unusual Options Activity For August 26
08/26/2024 18:15:37

novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets
Novo Nordisk's Ozempic Might Be Among 2027...
08/23/2024 18:21:18

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite co...

key-takeaways-from-abbvie-analyst-ratings
Key Takeaways From AbbVie Analyst Ratings
08/23/2024 15:01:02

piper-sandler-maintains-overweight-on-abbvie-raises-price-target-to-209
Piper Sandler Maintains Overweight on AbbV...
08/23/2024 14:24:34

Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $1...

unpacking-the-latest-options-trading-trends-in-abbvie
Unpacking the Latest Options Trading Trend...
08/20/2024 20:46:37

100-invested-in-this-stock-10-years-ago-would-be-worth-400-today
$100 Invested In This Stock 10 Years Ago W...
08/20/2024 15:00:17

Core News & Articles
Genmab A/S Announces TEPKINLY Has Received...
08/19/2024 18:01:48

TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both r...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
08/15/2024 17:35:23

Core News & Articles
AbbVie Announces EPKINLY Listing On Ontari...
08/15/2024 13:15:30

decoding-abbvies-options-activity-whats-the-big-picture
Decoding AbbVie's Options Activity: What's...
08/14/2024 17:00:38

cancer-focused-syros-pharmaceuticals-stops-mid-stage-leukemia-combo-therapy-study-cites-disappointing-unexpected-outcome
Cancer-Focused Syros Pharmaceuticals Stops...
08/13/2024 13:41:17

Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demons...

morgan-stanley-maintains-overweight-on-abbvie-raises-price-target-to-218
Morgan Stanley Maintains Overweight on Abb...
08/12/2024 17:29:19

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $211 to...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION